# Human Organoids Can Outpredict Animal Trials by Richard Socher > Parallel Bio uses pluripotent stem cells to grow human lymph-node organoids and test drugs in parallel. The organoids are designed to replace some animal trials by predicting human drug response and toxicity more directly than experiments in mice. > **— Adapted from Richard Socher**, *MOONSHOTS Live, October 2026* ## Sources and Context - **Recording or publication:** [MOONSHOTS Live at 17:27](https://www.youtube.com/watch?v=Blyb1D927pM&t=1047s) — The poster text is an explicit non-verbatim adaptation assembled from the source excerpts below. It preserves the speaker's argument while removing spoken-language filler, restoring the subject, and completing the mechanism or consequence needed for independent use. - **Exact transcript excerpt at [17:27](https://www.youtube.com/watch?v=Blyb1D927pM&t=1047s):** “And get this, if you love animals, you too can love AI. Why? Because they got FDA approval to skip animal trials. Turns out we cured most diseases in mice. It's not that helpful. They're very different to people. Uh, but these guys, uh, use pluripotent stem cells to create tiny little organoids of lymph nodes. Lymph nodes, big part of your immune system. Immunotherapy is some of the most exciting therapies to allow your own immune system to attack a cancer and so on, instead of getting crazy chemotherapy and so on. And so they got FDA approval because they showed that when you run experiments in parallel, hence ParallelBio, in these tiny petri dishes, how those organoids react to different drugs and toxicity testing and so on, is actually more predictive of how those drugs will interact in real human bodies. And that is just one of many beautiful examples-” - **Regulatory context:** [FDA roadmap for reducing animal testing](https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs) — the FDA identifies human organoids as a new-approach methodology that can reduce or replace some animal studies. This supports the general regulatory mechanism; it does not independently confirm the speaker's company-specific approval claim. - **Reconciled source dossier:** [[research/ASI and RSI Timeline Research Moonshots|ASI and RSI Timeline Research Moonshots]] — preserves broadcast order, speaker reconciliation, editorial conventions, and the surrounding argument from which this Reminder was promoted. ## Related Articles and Collections - **Collection:** [[collections/Simple Reminders|Simple Reminders]] - **Collection:** [[collections/Neurotech|Neurotech]] - **Article:** [[articles/Longevity Escape Velocity|Longevity Escape Velocity]] - **Article:** [[articles/Mechanistic Intelligence Is Humanity's Greatest Liberation|Mechanistic Intelligence Is Humanity's Greatest Liberation]] ## Related Topics - [[wiki/Richard Socher|Richard Socher]] - [[wiki/Parallel Bio|Parallel Bio]] - [[wiki/Patient-Derived Organoid|Patient-Derived Organoid]] ## Share on Social Media ``` Parallel Bio uses pluripotent stem cells to grow human lymph-node organoids and test drugs in parallel. The organoids are designed to replace some animal trials by predicting human drug response and toxicity more directly than experiments in mice. — Adapted from Richard Socher, MOONSHOTS Live, October 2026 https://bryantmcgill.com/simple-reminders-richard-socher-human-organoids-can-outpredict-animal-trials ```